Critical Therapeutic Objectives Continue to go Unmet for the Treatment of Multiple Sclerosis Even with the Assimilation of

EXTON, Pa.--(BUSINESS WIRE)-- Trial and share of Novartis’ Gilenya, the first oral disease-modifying agent (DMA) for the treatment of multiple sclerosis (MS), to grow suggesting increasing acceptance of Gilenya as part of the available armamentarium of DMAs. However, room exists for broader Gilenya education as almost one-half of Gilenya non-prescribers still do not know where or when they would use the DMA — presenting an obstacle to initial trial among these late adopters. And, even among prescribers, Gilenya tends to be reserved for second line use in patients who have efficacy or tolerability issues with other DMAs, an unenviable position also held by Biogen Idec’s Tysabri. For Tysabri, concern over liability issues associated with use of the product appears to be driving a strong agreement that the commercial availability of an anti-JC virus antibody assay would increase prescribing. For now, Teva’s Copaxone remains the market share leader within the DMA market, although it is no longer rated highest on product satisfaction or overall performance compared to the other DMAs. Copaxone and Biogen Idec’s Avonex are perceived as good choices for DMA-naïve patients with mild or moderately active disease, while Bayer’s Betaseron and Pfizer / EMD Serono’s Rebif are considered appropriate choices for DMA-naïve patients with more active disease.

Despite the availability of multiple DMAs, significant unmet needs remain. Reduction in disability progression, followed by improved efficacy and disease remission, continue to be considered the greatest unmet needs for DMAs in development. When asked about unmet needs not covered in the survey, neurologists clearly express a need for less expensive / more cost-effective DMAs. While interest is high for all seven DMAs in development profiled in this research, Biogen Idec’s BG-12 and Teva’s laquinimod are rated highest both on interest and on potential value brought to neurologists’ practice.

In the area of symptomatic management, three out of every four neurologists have initiated an MS patient on Acorda’s Ampyra after 18 months on the market, but less than one out five neurologists have tried Avanir’s Nuedexta in an MS patient seven-months post-launch stemming from major obstacles to Nuedexta trial including lack of appropriate patients and / or lack of product familiarity. When asked about products in development to treat spasticity associated with MS, significantly more neurologists perceive Otsuka’s Sativex and Impax’s IPX056 as potentially bringing the most value to their practice compared to XenoPort’s arbaclofen placarbil.

TreatmentTrends®: Multiple Sclerosis is a syndicated quarterly report series that provides a comprehensive view of the current and expected future management of multiple sclerosis (MS) based on primary research. The Q3 2011 wave was fielded with 99 neurologists in the U.S. in mid-August 2011. A parallel report covering the European market (EU5) is also available. These reports cover the use of disease-modifying agents for the treatment of MS, as well as attitudes and perceptions toward these products, advantages and disadvantages, ideal patient types, barriers to growth, and expected future use. In addition, respondents are queried about their awareness of and interest in DMAs and MS-related symptomatic products in development.

About BioTrends Research Group, LLC

BioTrends Research Group, LLC provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.



CONTACT:

BioTrends Research Group, LLC
Elisa Ferrante, 610-363-3872
[email protected]
or
Decision Resources Group
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.